InVivo Plus Anti-Mouse IL-17A Antibody(BZN035) (MS856019)

Name: InVivo Plus Anti-Mouse IL-17A Antibody(BZN035)
Brand: abinScience
SKU: MS856019
Price: 128 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

1mg
5mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	MS856019
Description	InVivo Plus Anti-Mouse IL17A Antibody (BZN035) [BZN035] (MS856019) is a mouse monoclonal antibody detecting Interleukin-17A in FCM, Neutralization. Suitable for Mouse. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Reactivité des espèces	Mouse
Applications	FCM, Neutralization
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG2a
ID de clone	BZN035
Cible	CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A
Niveau d'endotoxines	< 1 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q62386
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Contexte	Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). _x005F_x000D_ _x005F_x000D_ 1. Liang, SC. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 7791-9. PMID: 18025225 _x005F_x000D_ _x005F_x000D_ 2. Ishigame, H. et al. (2009) Immunity 30, 108-19. PMID: 19144317 _x005F_x000D_ _x005F_x000D_ 3. Lee, JS. et al. (2015) Immunity 43, 727-38. PMID: 26431948 _x005F_x000D_ _x005F_x000D_ 4. Park, H. et al. (2005) Nature immunology 6, 1133-41. PMID: 16200068 _x005F_x000D_ _x005F_x000D_ 5. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 _x005F_x000D_ _x005F_x000D_ 6. Chen, K. et al. (2016) Cell host & microbe 20, 596-605. PMID: 27923703 _x005F_x000D_
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Mouse IgG2a Recombinant Isotype Control Antibody (S43.10) (MF533307)